Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Revenue
Research and collaboration revenue	$ 795	$ 0	$ 3,150	$ 0
Operating Expenses:
Research and development	9,356	9,702	29,845	28,821
General and administrative	4,596	3,814	12,590	10,233
Impairment of right-of-use asset	494	0	494	0
Total operating expenses	14,446	13,516	42,929	39,054
Loss from operations	(13,651)	(13,516)	(39,779)	(39,054)
Other (expense) income, net:
Interest income	423	94	1,464	720
Change in fair value of derivative tranche liability	(1,800)	0	(1,800)	0
Other expense	(71)	(62)	(4)	(178)
Total other (expense) income, net	(1,448)	32	(340)	542
Net loss attributable to common stockholders	(15,099)	(13,484)	(40,119)	(38,512)
Comprehensive loss	$ (15,099)	$ (13,484)	$ (40,119)	$ (38,512)
Net loss per share attributable to common stockholders, basic, (in dollars per share)	$ (0.55)	$ (24.19)	$ (1.78)	$ (76.50)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.55)	$ (24.19)	$ (1.78)	$ (76.50)
Weighted-average shares of common stock outstanding, basic (in shares)	27,274,721	557,437	22,554,427	503,455
Weighted-average common shares outstanding, diluted (in shares)	27,274,721	557,437	22,554,427	503,455